ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Progenics Pharmaceuticals has taken full control of PSMA Development Co., its prostate cancer joint venture with Cytogen Corp. In addition to an upfront payment of $13.2 million, Cytogen stands to receive milestone payments of up to $52 million in exchange for its 50% share in the venture, which is developing cancer immunotherapies based on prostate-specific membrane antigen. Progenics gains PSMA antibody-drug-conjugate technology, as well as two PSMA therapeutic vaccine candidates.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter